Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword

Abstract Dehydrodiisoeugenol (DEH) is a primary benzofuran-type neolignan isolated from the Chinese herbal medicine nutmeg, which is used in the treatment of gastrointestinal diseases. This study aims to observe the dual therapeutic effects of DEH on DSS-induced ulcerative colitis (UC) and colorecta...

Full description

Saved in:
Bibliographic Details
Main Authors: Feiyang Yi, Nianzhi Chen, Maoyuan Zhao, Zhili Gu, Yun Yuan, Xuegui Tang, Fang Liu
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Molecular Medicine
Subjects:
Online Access:https://doi.org/10.1186/s10020-025-01193-7
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849724723439599616
author Feiyang Yi
Nianzhi Chen
Maoyuan Zhao
Zhili Gu
Yun Yuan
Xuegui Tang
Fang Liu
author_facet Feiyang Yi
Nianzhi Chen
Maoyuan Zhao
Zhili Gu
Yun Yuan
Xuegui Tang
Fang Liu
author_sort Feiyang Yi
collection DOAJ
description Abstract Dehydrodiisoeugenol (DEH) is a primary benzofuran-type neolignan isolated from the Chinese herbal medicine nutmeg, which is used in the treatment of gastrointestinal diseases. This study aims to observe the dual therapeutic effects of DEH on DSS-induced ulcerative colitis (UC) and colorectal cancer (CRC), with a focus on exploring the molecular mechanism by which DEH exerts anti-inflammatory effect in inflammatory cells and induces autophagy in CRC cells. An inflammatory cell model was established by LPS/IFNγ-stimulated RAW264.7 macrophages to observe the anti-inflammatory effect of DEH, while colon cancer cell lines were used to observe the anticancer activity of DEH. DSS-induced mice and subcutaneous tumor model in nude mice were also established to observe the bidirectional regulation of DEH. This study demonstrates that low concentrations of DEH exhibit anti-inflammatory effects in vitro. Importantly, DEH achieves significant inhibition of IκBα degradation and phosphorylation levels, as well as subsequent NF-κB nuclear translocation, while also suppressing the phosphorylation of the MAPK family members JNK, ERK, and p38, by reducing elevated NOD2 expression induced by LPS/IFNγ. In addition, oral administration of DEH improves colitis and colonic barrier damage in DSS-induced mice. Interestingly, at a high concentration of DEH significantly activates the NOD2 signaling pathway to promote autophagy and apoptosis in CRC cells, contributing to its anti-CRC effect. These findings suggest that different concentration of DEH shows bidirectional regulation by improve inflammatory responses in UC and simultaneously possess anti-CRC effects by targeting the NOD2. This highlights DEH as a promising candidate for clinical treatment of UC and CRC.
format Article
id doaj-art-c22db4c8d38e4c8baf665272ca09b872
institution DOAJ
issn 1528-3658
language English
publishDate 2025-06-01
publisher BMC
record_format Article
series Molecular Medicine
spelling doaj-art-c22db4c8d38e4c8baf665272ca09b8722025-08-20T03:10:39ZengBMCMolecular Medicine1528-36582025-06-0131111910.1186/s10020-025-01193-7Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged swordFeiyang Yi0Nianzhi Chen1Maoyuan Zhao2Zhili Gu3Yun Yuan4Xuegui Tang5Fang Liu6Clinical Medicine College of Integrated Chinese and Western Medicine, North Sichuan Medical CollegeShuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineSchool of Chinese Materia Medica, Beijing University of Chinese MedicineClinical Medicine College of Integrated Chinese and Western Medicine, North Sichuan Medical CollegeHospital of Chengdu University of Traditional Chinese MedicineClinical Medicine College of Integrated Chinese and Western Medicine, North Sichuan Medical CollegeClinical Medicine College of Integrated Chinese and Western Medicine, North Sichuan Medical CollegeAbstract Dehydrodiisoeugenol (DEH) is a primary benzofuran-type neolignan isolated from the Chinese herbal medicine nutmeg, which is used in the treatment of gastrointestinal diseases. This study aims to observe the dual therapeutic effects of DEH on DSS-induced ulcerative colitis (UC) and colorectal cancer (CRC), with a focus on exploring the molecular mechanism by which DEH exerts anti-inflammatory effect in inflammatory cells and induces autophagy in CRC cells. An inflammatory cell model was established by LPS/IFNγ-stimulated RAW264.7 macrophages to observe the anti-inflammatory effect of DEH, while colon cancer cell lines were used to observe the anticancer activity of DEH. DSS-induced mice and subcutaneous tumor model in nude mice were also established to observe the bidirectional regulation of DEH. This study demonstrates that low concentrations of DEH exhibit anti-inflammatory effects in vitro. Importantly, DEH achieves significant inhibition of IκBα degradation and phosphorylation levels, as well as subsequent NF-κB nuclear translocation, while also suppressing the phosphorylation of the MAPK family members JNK, ERK, and p38, by reducing elevated NOD2 expression induced by LPS/IFNγ. In addition, oral administration of DEH improves colitis and colonic barrier damage in DSS-induced mice. Interestingly, at a high concentration of DEH significantly activates the NOD2 signaling pathway to promote autophagy and apoptosis in CRC cells, contributing to its anti-CRC effect. These findings suggest that different concentration of DEH shows bidirectional regulation by improve inflammatory responses in UC and simultaneously possess anti-CRC effects by targeting the NOD2. This highlights DEH as a promising candidate for clinical treatment of UC and CRC.https://doi.org/10.1186/s10020-025-01193-7Ulcerative colitisColorectal cancerDehydrodiisoeugenolNOD2
spellingShingle Feiyang Yi
Nianzhi Chen
Maoyuan Zhao
Zhili Gu
Yun Yuan
Xuegui Tang
Fang Liu
Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword
Molecular Medicine
Ulcerative colitis
Colorectal cancer
Dehydrodiisoeugenol
NOD2
title Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword
title_full Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword
title_fullStr Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword
title_full_unstemmed Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword
title_short Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword
title_sort dehydrodiisoeugenol targets nod2 exerting dual effects against colitis and colorectal cancer a double edged sword
topic Ulcerative colitis
Colorectal cancer
Dehydrodiisoeugenol
NOD2
url https://doi.org/10.1186/s10020-025-01193-7
work_keys_str_mv AT feiyangyi dehydrodiisoeugenoltargetsnod2exertingdualeffectsagainstcolitisandcolorectalcanceradoubleedgedsword
AT nianzhichen dehydrodiisoeugenoltargetsnod2exertingdualeffectsagainstcolitisandcolorectalcanceradoubleedgedsword
AT maoyuanzhao dehydrodiisoeugenoltargetsnod2exertingdualeffectsagainstcolitisandcolorectalcanceradoubleedgedsword
AT zhiligu dehydrodiisoeugenoltargetsnod2exertingdualeffectsagainstcolitisandcolorectalcanceradoubleedgedsword
AT yunyuan dehydrodiisoeugenoltargetsnod2exertingdualeffectsagainstcolitisandcolorectalcanceradoubleedgedsword
AT xueguitang dehydrodiisoeugenoltargetsnod2exertingdualeffectsagainstcolitisandcolorectalcanceradoubleedgedsword
AT fangliu dehydrodiisoeugenoltargetsnod2exertingdualeffectsagainstcolitisandcolorectalcanceradoubleedgedsword